CinCor Pharma

CinCor Pharma is a clinical-stage biopharmaceutical company targeting cardiovascular, metabolic, and kidney diseases. It develops CIN-107, an oral small-molecule inhibitor of aldosterone synthase, that works through the renin-angiotensin-aldosterone system (RAAS), which is responsible for regulating the body’s fluid and electrolyte balance.